Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) dropped 3.5% on Friday. The stock traded as low as $11.03 and last traded at $11.07. Approximately 953,156 shares changed hands during trading, an increase of 96% from the average daily volume of 486,688 shares. The stock had previously closed at $11.47.
Eliem Therapeutics Stock Performance
The stock has a market capitalization of $329.35 million, a PE ratio of -20.89 and a beta of -0.39. The business’s 50-day moving average is $14.16 and its two-hundred day moving average is $11.68.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc is a biotechnology company focused on developing therapies for disorders of the nervous system. Its research has centered on treatments for neurological and psychiatric conditions, including pain, epilepsy, depression and other diseases involving the central and peripheral nervous systems.
The company’s former development programs included ETX-155, an investigational neurosteroid intended to modulate GABA-A receptors for potential use in depressive disorders, and ETX-810, a prodrug candidate designed to address neuropathic pain and related conditions.
See Also
- Five stocks we like better than Eliem Therapeutics
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
